Close menu




October 23rd, 2019 | 07:54 CEST

AURORA, BEVCANNA, EXMCEUTICALS - CANADA GETTING READY FOR CANNABIS 2.0

  • Cannabis
Photo credits: pixabay.com

The consulting firm Deloitte has taken a close look at the cannabis industry and evaluated food and extracted products for the cannabis 2.0 market. In their analysis, the experts came to the conclusion that the annual Canadian market for food and alternative cannabis products is worth CAD 2.7 billion. The vast majority of this emerging cannabis 2.0 market will be products based on cannabis extracts, including foods, which the analysis puts at CAD 1.6 billion alone. But there are other significant opportunities, including cannabis-infused beverages with CAD 529 million, health products with CAD 174 million, concentrates with CAD 140 million, tinctures with CAD 116 million and capsules with CAD 114 million.

time to read: 1 minutes | Author: Mario Hose
ISIN:

Table of contents:


    LEGALIZATION PROVIDES FOUNDATION FOR NEW MARKETS

    The realisation of this considerable market potential will take some time, according to the Deloitte experts, because many cannabis products in these categories will only be available in sufficient quantities over time. Deloitte's industry representatives see cannabis 2.0 as a catalyst for the Canadian market, which is divided into two different target groups, in the context of further legalisation in October 2019.

    Firstly, experienced cannabis users, such as millennials and younger people, already consume cannabis several times a week and are open to new products.

    NEW CONSUMER GROUPS OFFER POTENTIAL

    As the second target group of a new cannabis boom, the Deloitte experts see the beginners and the curious. Usually they are not interested in flammable cannabis. This new conservative type of user, typically middle-aged and university educated, focuses on family needs or other responsibilities and consumes cannabis less than once a month.

    These consumers are expected to be attracted to more familiar formats, particularly foods such as baked goods, confectionery and teas. The low doses available in food and micro-doses are ideal for these consumers and provide a more convenient starting point for their cannabis experience.

    NEW COMPANIES OFFER FAVOURABLE VALUATIONS

    The outlined development of the cannabis 2.0 market becomes interesting in connection with the increasing legalization of cannabis products around the globe and against this background not only the first series like Aurora and Canopy Growth are exciting, but also the innovative new players with interesting business models or cost-efficient structures. In recent years, the young companies have been able to learn from the weaknesses and strengths of the already established billion-euro companies.

    BevCanna Enterprises Inc., a developer and manufacturer of cannabinoid-based beverages and consumer goods for private labels and white label customers, is just as interesting as EXMceuticals Inc., a company that produces CBD of the highest quality in various African countries and wants to offer it in large quantities worldwide. The two companies are currently valued at less than CAD 50 million on the stock exchange. Jonathan Summers, Chairman of EXMceuticals, will present the company this year at the German Equity Forum in Frankfurt. If Deloitte's market assessment proves to be true and this trend continues globally, then these two companies will certainly be attractively valued from today's perspective. We will see.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Nico Popp on February 2nd, 2023 | 18:04 CET

    Bulging pipeline at BioNTech, Cardiol Therapeutics - what is the problem at Aurora Cannabis?

    • Biotechnology
    • Cannabis
    • Cancer

    He who heals is right. It is not quite that simple with active ingredients that are about to be approved. Drugs and vaccines must undergo extensive studies and, last but not least, have to prevail against the existing competition. We look at the pipelines of three hot stocks and venture a forecast: Where is the greatest potential for investors?

    Read

    Commented by Fabian Lorenz on December 1st, 2022 | 11:55 CET

    Comeback stocks: Nel, Aurora Cannabis, Barrick Gold, Tocvan Ventures

    • Mining
    • Gold
    • Hydrogen
    • Cannabis

    Gold, cannabis and hydrogen could be among the top trends of the coming year - also on the stock market. Due to full order books, Nel could be poised for a comeback in 2023. At least sales are already secured until mid-2024. Now, all that is left is to cut the loss to reach analysts' price targets. Aurora Cannabis has largely completed its turnaround and is also hoping for legalization in Europe and the US. Driven by a strong gold price, mining stocks have already jumped. Now exploration companies should follow. Tocvan Ventures is one of them. And with the gold explorer, investors can look forward to a regular news flow in the coming year. Are the three candidates comeback stocks in 2023?

    Read

    Commented by Stefan Feulner on November 28th, 2022 | 10:41 CET

    SynBiotic SE, Cardiol Therapeutics, Canopy Growth - Like hitting the jackpot

    • Cannabis
    • Investments

    The final draft of the German government's key issues paper on the legalization of cannabis in Germany is ready, and final approval is likely to be a mere formality. For the companies concerned, this is equivalent to winning the lottery. The global cannabis market is expected to grow by 13.9% annually to USD 64.91 billion between 2022 and 2027. However, these profit increases have yet to reach the stock market. Some companies, for example, are trading below cash, while others lost more than 90% of their value in the correction that has been underway since 2019.

    Read